Form 4: Boston Scientific CEO Michael Mahoney Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Michael Mahoney, Chairman, President & CEO of Boston Scientific, exercised stock options and sold shares of common stock on May 1, 2025, under a pre-established Rule 10b5-1 trading plan.
Summary
- On May 1, 2025, Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corp, executed stock options to acquire 56,212 shares at $17.26 and 49,407 shares at $24.55.
- He then sold 73,161 shares at a weighted average price of $102.9197 and 91,282 shares at a weighted average price of $102.126.
- These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 15, 2024.
- Following these transactions, Mahoney directly owns 1,535,706 shares of common stock and indirectly owns 201,478 shares through a trust.
- He also holds options to purchase 56,212 shares at $17.26 and 197,628 shares at $24.55.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Future Outlook
The document does not contain specific forward-looking statements, but it indicates ongoing transactions under a pre-established trading plan.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use Rule 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across publicly traded companies, including Boston Scientific's competitors such as Medtronic (MDT), Abbott Laboratories (ABT), and Johnson & Johnson (JNJ).
- Rule 10b5-1 trading plans are a standard tool used by executives at these companies to manage their personal finances and avoid insider trading concerns.
- The size and frequency of these transactions are typical for executives at companies of Boston Scientific's size and market capitalization.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-established trading plan mitigates concerns about insider trading.
- The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2017-02-22 | First anniversary of option grant vesting in four equal annual installments. |
| 2018-02-28 | First anniversary of option grant vesting in four equal annual installments. |
| 2024-11-15 | Adoption date of Rule 10b5-1 trading plan. |
| 2025-05-01 | Date of stock option exercise and share sale transactions. |
| 2025-05-05 | Date of Form 4 filing. |
| 2026-02-22 | Expiration date of stock options. |
| 2027-02-28 | Expiration date of stock options. |
Keywords
Form 4, Michael Mahoney, Boston Scientific, BSX, Stock Options, Share Sale, Rule 10b5-1, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.